Using Antibiotics in the Lungs to Prevent Pneumonia in ICU Patients
Author Information
Author(s): Matthew E. Falagas, Ilias I. Siempos, Ioannis A. Bliziotis, Argyris Michalopoulos
Primary Institution: Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece
Hypothesis
Does administering prophylactic antibiotics via the respiratory tract reduce the incidence of ICU-acquired pneumonia?
Conclusion
Prophylactic administration of antibiotics via the respiratory tract is associated with a reduction in ICU-acquired pneumonia, but may increase the emergence of resistant bacteria.
Supporting Evidence
- ICU-acquired pneumonia was less common in patients receiving antibiotic prophylaxis.
- No significant difference in mortality was found between the groups.
- Fewer patients were colonized with Pseudomonas aeruginosa in the prophylaxis group.
- No serious drug-related toxicity was noted.
- Limited evidence suggests an increase in resistant bacteria with prophylactic use.
Takeaway
Giving antibiotics through the lungs can help prevent pneumonia in patients in intensive care, but it might also lead to more germs that don't respond to treatment.
Methodology
A meta-analysis of 8 comparative trials, including 5 randomized controlled trials and 3 non-randomized trials, was conducted to evaluate the effects of prophylactic antibiotics administered via the respiratory tract.
Potential Biases
Potential bias due to the inclusion of studies with varying methodologies and quality.
Limitations
The studies included were from different time periods and varied in quality, and there was limited data on the emergence of resistance.
Participant Demographics
Patients in intensive care units, primarily mechanically ventilated.
Statistical Information
P-Value
0.49 for ICU-acquired pneumonia, 0.86 for mortality
Confidence Interval
0.32–0.76 for ICU-acquired pneumonia, 0.55–1.32 for mortality
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website